Wednesday 17 May

Wednesday 17 May


08:00 - 08:45 Sponsored breakfast meeting II

Please view more detailed information about this program item under the tab sponsored sessions.


08:00 - 08:45 [CLOSED MEETING] BORNEO Group

08:00 - 08:45 Educational Session 2


Immunotherapy for NB - GD2, CAR-T and all the other options

John Anderson, UK


Tumor microenvironment in NB

Yves Declerck, United States

09:00 - 10:00 Plenary session 5: Immune therapy

Moderators: Julie Park, United States & John Anderson, United Kingdom


PS5.1 Bispecific SNIPER Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma

Paul Sondel, United States


PS5.2 Integrative analysis of neuroblastoma by single‐cell RNA sequencing identifies the NECTIN2‐TIGIT axis as a target for immunotherapy

Judith Wienke, the Netherlands


PS5.3 Multi-antigen targeting of neuroblastoma with CAR T-cells secreting bispecific innate immune cell engagers

Guillem Pascual-Pasto, United States


PS5.4 A novel B7H3 targeting chimeric antigen receptor regulated by an IMiD drug sensitive degron tag, optimised for neuroblastoma immunotherapy

Sophie Munnings-Tomes, UK

10:00 - 10:50 Parallel session 11: Immune Therapy

Moderators: Juliet Gray, United Kingdom & Annette Künkele, Germany


O11.1 Depletion of CD11b+ myeloid cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody dinutuximab beta

Leon von Lojewski, Germany


O11.2 T cell mediated killing of neuroblastoma is inhibited by secreted midkine

Josephine Strijker, the Netherlands


O11.3 Allogeneic CAR T cells targeting GD2 for Treatment of Relapsed/Refractory High-Risk Neuroblastoma

Francesca del Bufalo, Italy


O11.4 Library-based Discovery of Peptide-centric CAR T Cells for Neuroblastoma (NB)

Quinlen Marshall, United States

10:00 - 10:50 Parallel session 12: Stem cell derived models to study NB

Moderators: Katleen De Preter, Belgium & Frank Speleman, Belgium


O12.1 Identification of genetic drivers of relapse in MYCN driven neuroblastoma

Miller Huang, United States


O12.2 Single-cell transcriptome and epigenome analysis in a stem cell model reveal developmental impact of neuroblastoma-associated chromosomal aberrations

Florian Halbritter, Austria


O12.3 Maintenance of pluripotency in the entire ectoderm enables neural crest formation – insights from normal development to help understand neuroblastoma

Laura Kerosuo, United States


O12.4 Modelling neuroblastoma using germline ALK-R1275Q mutant patient-derived induced pluripotent stem cells

Mingzhi Liu, Sweden


10:50 - 11:20 Coffee break

11:20 - 12:25 Parallel session 13: Precision therapy: Novel combinations

Moderators: Godfrey Chan, Hong Kong & Emmy Dolman, Australia


O13.1 Combining venetoclax with lorlatinib leads to complete responses in multiple neuroblastoma models with high BCL-2 expression and ALK mutation.

Lindy Vernooij, the Netherlands


O13.2 Combining Notch blockade with High-dose radiation therapy (HDRT) and immunotherapy (IO) results in a synergistic growth inhibition of NB tumors.

Debarshi Banerjee, United States


O13.3 The CDK7/CDK9 and CKIα co-inhibitor exerts efficacious anticancer effects against TERT gene-rearranged neuroblastoma

Tao Liu, Australia


O13.4 Dual-selective pharmacotherapy achieves profound and lasting tumor growth suppression in experimental models of MYCN-amplified neuroblastoma

Michael Chorny, United States

11:20 - 12:25 Parallel session 14: Clinical trials for relapsed neuroblastoma

Moderators: Pablo Berlanga, France & Lucas Moreno, Spain


O14.1 Circulating adrenergic neuroblastoma mRNAs predict outcomes in children with relapsed and refractory neuroblastoma; a BEACON-Neuroblastoma biomarker study

Sue Burchill, UK


O14.2 Significantly improved PFS in relapsed/refractory neuroblastoma adding molecular targeted drugs to Irinotecan/Temozolomide: Results of a randomized phase II trial (RIST)

Selim Corbacioglu, Germany


O14.3 Phase I Study of 131I-MIBG with Dinutuximab +/- Vorinostat for Patients with Relapsed or Refractory Neuroblastoma (NANT 2017-01)

Thomas Cash, United States


O14.4 Norepinephrine transporter and vesicular monoamine transporter-2 tumor expression as a predictor of response to 131I-MIBG in patients with relapsed/refractory neuroblastoma

Vandana Batra, United States


O14.5 Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase I trial results and insights into mechanisms of resistance through tracking of serial circulating tumor DNA

Yael Mossé, United States

12:25 - 12:40 Rapid Fire session 2A

Moderator: Ellen Westerhout, the Netherlands


P215 Peptide-centric CAR T cell therapy targeting the tumor-associated antigen PRAME

Erin Runbeck, United States


P208 IgA3.0 ch14.18 antibodies are effective in preclinical neuroblastoma models without inducing neuropathic pain

Marjolein Stip, the Netherlands


P212 Antigen-driven cytokine expression systems to enhance the function and overcome challenges of CAR T cell therapy in neuroblastoma

Reona Okada, United States


P213 Desensitizing the Autonomic Nervous System to mitigate anti-GD2 Monoclonal Antibody Side Effects

Jaume Mora, Spain


P209 Best of two worlds: Engineering NKT-cells to generate an alternative adaptive cell therapy strategy against neuroblastoma

Annelisa Cornel, the Netherlands


P211 Immunomodulatory effect of the MEK pathway inhibitor enhanced the efficacy of GD2-CAR-T cell therapy against neuroblastoma

Akimasa Tomida, Japan


P210 GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma

Kristopher Bosse, United States


P130 A zebrafish larvae xenograft model for high-throughput drug testing and precision medicine in neuroblastoma

Joshua Robert Goulding, Belgium


P129 Pseudometastatic allografting of TH-MYCN neuroblastoma cells with loss of p53 function provides an efficient syngeneic model of advanced-stage, high-risk disease

Garrett Brodeur, United States


P128 Unbiased high-throughput screening and preclinical testing in PDX models identifies synergistic combinations with the BCL2 inhibitor venetoclax

Jamie Fletcher, Australia


12:40 - 13:40 Lunch & Poster Session Group C

Posters with reference P192 until P270


Social program

Based on pre registration